-
No Cytokine on This Pathway Touches Bone(Post)
Not one immune cytokine on this pathway touches bone. TNF, IL-1β, IL-6 and IL-17A all act on osteoblasts, osteocytes and synovial fibroblasts, and it is those stromal cells that decide between RANKL
TNF Receptor Superfamily: TNFR1 vs TNFR2(Page) Mycoplasma in Cell Culture Detection Guide(Post)As a PhD student delving deep into the realm of cellular biology, there is one antagonist that consistently challenges my research: mycoplasma. This microscopic bacterium, with its a
Custom Antibody(Page)Custom Antibody Production Service | Assay Genie
Adenosine Axis — CD39, CD73 and A2A Receptors(Page) C-Reactive Protein (CRP): Function, Levels & What They Mean(Post)Biomarkers · InflammationC-Reactive Protein (CRP): Structure, Function and Clinical UseCRP is the most widely measured marker of inflammation in medicine — fast to rise, fast to fall, and entirely non
Ferroptosis Assays(Page)Ferroptosis Assay Kits | Lipid Peroxidation, Iron & Glutathione | Assay Genie
Site Directed Mutagenesis(Page)Site-Directed Mutagenesis | Protocol, Kits & Troubleshooting | Assay Genie
COVID-19(SARS-CoV-2)トリプレックスRT-qPCR検出キット| Assay Genie(Post)COVID-19(SARS-CoV-2)トリプレックスRT-qPCR検出キット COVID-19アッセイの概要: この製品は、新規コロナウイルスSARS-CoV-2によって引き
Ozuriftamab: A Closer Look at This Anti-CD47 Antibody in Cancer Immunotherapy(Post)What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer c
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research(Post)Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond(Post)What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
SOCS proteins: Manipulating the immune response(Post)Katherine Edwards, PhD Student, Queen’s University Belfast Cytokines play a vital role in immune responses enabling cross-talk between different cell types a
Understanding the mTOR Signaling Pathway: A Key Player in Cell Growth and Metabolism(Post)Cell Signalling · MetabolismThe mTOR Signalling PathwaymTOR is a master regulator of cell growth, metabolism and survival, integrating nutrient, growth-factor and energy signals through two comp
Advantages of Small Molecule Inhibitors in Therapeutic Interventions(Post)Small molecule inhibitors represent a significant advancement in the field of therapeutic interventions, offering a versatile approach to treating a myriad of diseases, including cancer, viral inf
Dendritic Cells - Markers, Activation & Subtypes(Post)Immunology · Antigen PresentationDendritic Cells: Markers, Activation and SubtypesDendritic cells are the professional antigen-presenting cells that decide whether an immune response happens at all. T
Mesenchymal Stem Cell Differentiation Pathways: Unraveling Lineage-Specific Markers(Post)The intricate process of mesenchymal stem cell (MSC) differentiation is a cornerstone of developmental biology and regenerative medicine. Mesenchymal stem cells, renowned for their self-renewal ca
Hippo Pathway Review(Post)MST2/Hippo PathwayMammalian Sterile Twenty (MST) pathways have been identified as a homologue of the ste20 kinase from Saccharomyces cerevisiae (Creasy and Chernoff 1995). The MST2/Hippo pathway
Beyond Burnout: How T Cell Exhaustion Hijacks Cancer Immunity and What We Can Do About It(Post)Imagine a highly trained soldier, elite and effective, sent to the front lines of a relentless war. Day after day, they fight without rest, their supplies dwindle, and the enemy never stops coming. Ev
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli